SCHEMBL2215765

SCHEMBL2215765

CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.71

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AR P10275 10/20 0.71
PPARG P37231 1/20 0.51
PPARD Q03181 1/20 0.51
PPARA Q07869 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2217636 0.91 AR (0.58) ARPPARGPPARDPPARA
SCHEMBL2217887 0.88 AR (0.55) ARPPARGPPARDPPARA
SCHEMBL2217757 0.85 AR (0.66) AR
SCHEMBL2218688 0.83 PPARG (0.52) ARPPARGPPARDPPARA
SCHEMBL2215038 0.83 AR (0.66) AR
SCHEMBL2218832 0.82 AR (0.66) AR
SCHEMBL2216680 0.82 AR (0.65) AR
SCHEMBL1773400 0.81 AR (0.62) ARPPARGPPARDPPARA
SCHEMBL12603231 0.80 AR (0.71) AR
SCHEMBL8021677 0.80 TAS2R8 (0.54) ARPPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178134-A1 Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof SANOFI-AVENTIS (FR) 2011-07-21 US claimed
EP-2242745-A1 NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF Sanofi-Aventis (FR) 2010-10-27 EP claimed
WO-2009097995-A1 NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO claimed
US-20110178134-A1 Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof SANOFI-AVENTIS (FR) 2011-07-21 US disclosed
US-20110178134-A1 Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof SANOFI-AVENTIS (FR) 2011-07-21 US disclosed
US-20110178134-A1 Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof SANOFI-AVENTIS (FR) 2011-07-21 US disclosed
EP-2242745-A1 NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF Sanofi-Aventis (FR) 2010-10-27 EP disclosed
WO-2009097995-A1 NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed
WO-2009097995-A1 NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178134-A1 Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof FABP4, GPR119, PGC AR 3140/4885PPARG 17/4885PPARD 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.